XML 20 R9.htm IDEA: XBRL DOCUMENT
v3.22.1

Condensed Consolidated Financial Statement Detail | 3 Months Ended
--- | ---
Mar. 31, 2022
Condensed Consolidated Financial Statement Detail |
Condensed Consolidated Financial Statement Detail | 3. Condensed Consolidated Financial Statements Details Equity Securities As of March 31, 2022 and December 31, 2021, equity securities consisted of an investment in Rezolute’s common stock of $0.5 million and $0.8 million, respectively (Note 4). For the three months ended March 31, 2022 and 2021, the Company recognized a loss of $0.2 million and $0.7 million, respectively, due to the change in fair value of its investment in Rezolute’s common stock in the other (expense) income, net line item of the condensed consolidated statements of operations and comprehensive loss. Accrued and Other Liabilities Accrued and other liabilities consisted of the following (in thousands): ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | March 31, | ​ | December 31,
​ |  | 2022 |  | 2021
Accrued legal and accounting fees | ​ | ​ | 445 | ​ | ​ | 295
Accrued incentive compensation | ​ | ​ | 231 | ​ | ​ | 55
Accrued payroll and benefits | ​ |  | 129 | ​ |  | 135
Other accrued liabilities | ​ | ​ | 50 | ​ | ​ | 40
Total | ​ | $ | 855 | ​ | $ | 525
​ Net Loss Per Share Attributable to Common Stockholders The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the calculation of basic and diluted net loss per share attributable to common stockholders (in thousands, except per share amounts): ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31,
​ |  | 2022 |  | 2021
Numerator |  | ​ |  |  | ​ |
Net loss | ​ | $ | (2,280) | ​ | $ | (7,373)
Less: Series A accumulated dividends | ​ |  | (530) | ​ |  | (530)
Less: Series B accumulated dividends | ​ | ​ | (838) | ​ | ​ | —
Net loss available to common stockholders, basic and diluted | ​ | $ | (3,648) | ​ | $ | (7,903)
​ | ​ | ​ | ​ | ​ |  | ​
Denominator | ​ |  | ​ | ​ |  | ​
Weighted average shares used in computing basic and diluted net loss per share available to common stockholders | ​ |  | 11,330 | ​ |  | 11,240
Basic and diluted net loss per share available to common stockholders | ​ | $ | (0.32) | ​ | $ | (0.70)
​ Potentially dilutive securities are excluded from the calculation of diluted net loss per share available to common stockholders if their inclusion is anti-dilutive. The following table shows the weighted-average shares from outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share attributable to common stockholders (in thousands): ​
​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31,
​ |  | 2022 |  | 2021
Convertible preferred stock | ​ | 5,003 | ​ | 5,003
Common stock options |  | 697 | ​ | 277
Warrants for common stock |  | 6 | ​ | 5
Total |  | 5,706 |  | 5,285
​

X
- Definition The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement. + References No definition available. + Details
Name: | us-gaap_AdditionalFinancialInformationDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Consolidated financial statement detail. + References No definition available. + Details
Name: | xoma_ConsolidatedFinancialStatementDetailAbstract
Namespace Prefix: | xoma_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration